The Value of High-Efficacy Therapy (HET) for MS Patients
Session Moderators:
Prof. Ugur Uygunoglu & Prof. Nikolaos Grigoriadis
Speakers & Presentation Flow:
Prof. Dr. Uroš Rot – “Societal Value: Addressing the broader impact on patient lives and healthcare systems.”
Prof. Rodica Ioana Bălașa – “Ocrelizumab as HET: Demonstrating the clinical value and long-term outcomes for patients.”
Acad. Prof. Ivan Milanov – “Ocrelizumab SC: Focus on the latest Efficacy and Safety data.”
Discussion